BioCentury | Nov 26, 2018
Distillery Therapeutics

Infectious disease

...neutralizing activity against Zika virus showed the mAb bound sequences on EDIII that form the EDI-EDIII...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Patient sample, cell culture and macaque studies identified a combination of mAbs against EDII and EDIII that could help treat Zika infection. Screening of mAb clones derived from blood plasmablasts of a...
BioCentury | Feb 8, 2017
Distillery Techniques

Drug platforms

...the other mAb revealed binding interactions involving Zika virus EDI and the hinge region between EDI...
...EDII . Next steps could include using the structural information to develop therapeutic mAbs against EDI...
...F. Gao, same affiliation as above email: Karen Tkach Chinese Academy of Sciences Zika virus envelope protein (Env) Zika virus envelope protein domain I (EDI) Zika...
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Zika virus envelope protein domain III (EDIII)

Infectious disease INDICATION: Viral infection Patient sample, cell culture and mouse studies identified an anti- EDIII mAb that could help prevent or treat Zika viral infection. A cell culture-based screen of 119 anti-EDIII mAbs derived...
BioCentury | Aug 11, 2014
Financial News

Enumeral Biomedical completes private placement of units

...$21.5 million Units: 21.5 million Price: $1 (unit) Shares after offering: 50.1 million Placement agent: EDI...
BioCentury | Aug 5, 2014
Financial News

Enumeral raises $21.5M, reverse-merges

...a five-year warrant to purchase a share at $2. Montrose Capital Partner led the offering. EDI...
BioCentury | Jun 30, 2014
Company News

Edimer, InformedDNA deal

Informed Medical Decisions (InformedDNA) developed a genetic counseling program for patients and families affected by X-linked hypohydrotic ectodermal dysplasia (XLHED) in which InformedDNA may identify individuals that may benefit from treatment with Edimer’s EDI200 . As...
BioCentury | Oct 14, 2013
Financial News

Neurotrope completes private placement of convertible preferred stock

...placement of convertible preferred stock Raised: $1.1 million Shares: 1.1 million Price: $1 Placement agents: EDI...
BioCentury | Oct 14, 2013
Clinical News

Fc-EDA1: Phase II started

Edimer began an open-label, dose-escalation, international Phase II trial to evaluate 3 and 10 mg/kg EDI200 in about 6 male newborns with XLHED. Dosing will begin between days 2 and 14 after birth with each...
BioCentury | Jul 31, 2013
Financial News

Edimer secures $18M in series B

Edimer Pharmaceuticals Inc. (Cambridge, Mass.) secured $18 million in a tranched series B round led by new investor New Enterprise Associates (NEA). New investor Sanofi-Genzyme BioVentures also participated, along with existing investors Third Rock Ventures...
Items per page:
1 - 10 of 16